Drugs / BP2202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07667868 | Oct 2026 → Dec 2027 expected | refractory plasma cell neoplasm | BrightPath Biotherapeutics | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-02 | BrightPath Biotherapeutics | Regulatory BP2202に係る米国食品医薬品局(FDA)への治験申請(IND)提出のお知らせ brightpathbio.com ↗ |
| 2025-07-03 | BrightPath Biotherapeutics | Regulatory 多発性骨髄腫の治療薬候補「BP2202」が米国FDAよりオーファンドラッグ指定を取得 brightpathbio.com ↗ |
| 2025-05-14 | BrightPath Biotherapeutics | Results BCMA CAR-ipsNKT細胞（BP2202）の製造工程開発の進捗に関するデータを米国遺伝子治療学会議ASGCT 2025で発表 brightpathbio.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | BrightPath Biotherapeutics | iPS細胞由来BCMA CAR-NKT細胞療法（BP2202）の非臨床研究成果と第I相臨床試験のデザインをIMS 2026で発表 brightpathbio.com ↗ |
| 2026-09-08 | BrightPath Biotherapeutics | 「iPS細胞由来BCMA CAR-NKT細胞療法（BP2202）の非臨床研究成果を IMS 2026で発表予定」 brightpathbio.com ↗ |
| 2026-07-02 | BrightPath Biotherapeutics | BP2202に係る米国食品医薬品局(FDA)への治験申請(IND)提出のお知らせ brightpathbio.com ↗ |
| 2025-07-03 | BrightPath Biotherapeutics | 多発性骨髄腫の治療薬候補「BP2202」が米国FDAよりオーファンドラッグ指定を取得 brightpathbio.com ↗ |
| 2025-05-14 | BrightPath Biotherapeutics | BCMA CAR-ipsNKT細胞（BP2202）の製造工程開発の進捗に関するデータを米国遺伝子治療学会議ASGCT 2025で発表 brightpathbio.com ↗ |
| 2025-05-08 | BrightPath Biotherapeutics | iPS細胞由来BCMA CAR-NKT細胞(BP2202)の製造工程開発に関するデータをASGCT 2025で発表予定 brightpathbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP2202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07667868 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT07667868 ↗ |